Abordarás Enfermedades Neurológicas de alto impacto, como Epilepsia, Migraña y Miastenia Gravis, mediante un enfoque clínico integral, con terapias emergentes y estrategias innovadoras en un programa 100 % online” 

Los pacientes que padecen desde Patologías De Alta Incidencia como la Epilepsia, las frecuentes Migrañas o la Enfermedad Autoinmune Miastenia Gravis han encontrado en los avances farmacológicos importantes mejoras en sus tratamientos y diagnósticos. En este sentido, los estudios en torno a las Enfermedades Neurológicas han permitido optimizar la calidad de vida de las personas afectadas e incorporar a la práctica clínica los adelantos más relevantes. 

En este contexto, los profesionales farmacéuticos, especialmente aquellos en entornos hospitalarios, deben estar al tanto de los avances más recientes, las técnicas empleadas en el manejo del paciente y la farmacología aplicada. Con este propósito, se ha diseñado el Postgraduate diploma en Advanced Neuropharmacology, estructurado sobre un plan de estudios que proporciona información avanzada sobre la fisiopatología y los fármacos utilizados en las principales Enfermedades del Sistema Nervioso Central, así como los empleados en el manejo de Convulsiones y Cefaleas. Además, se hace especial énfasis en los tratamientos para pacientes quirúrgicos y politraumatizados. 

Este programa universitario ofrece vídeo resúmenes de cada tema, vídeos “in focus”, casos de estudio y lecturas especializadas, que permiten ampliar los conocimientos proporcionados en el temario. Todo ello se presenta en una plataforma virtual flexible, accesible desde cualquier dispositivo con conexión a internet, permitiendo al profesional conciliar su actividad diaria con la actualización constante en farmacología neurológica avanzada. Este enfoque práctico y vanguardista garantiza que el profesional adquiera competencias sólidas, integrando terapias emergentes y estrategias innovadoras en la atención de pacientes con condiciones neurológicas complejas. 

Asimismo, el Postgraduate diploma incorpora la metodología Relearning de TECH y se complementa con Masterclasses impartidas por un Director Invitado Internacional, que profundiza en casos clínicos reales, técnicas avanzadas de tratamiento y protocolos farmacológicos especializados, reforzando los contenidos del plan de estudios y asegurando un aprendizaje aplicado, directamente trasladable al entorno clínico. 

Participarás en una serie de Masterclasses con un Director Invitado Internacional, dominando casos clínicos reales, técnicas avanzadas y protocolos farmacológicos para potenciar tu desempeño en el ámbito clínico”  

Esta Postgraduate diploma en Advanced Neuropharmacology contiene el programa universitario más completo y actualizado del mercado. Sus características más destacadas son: 

• El desarrollo de casos prácticos presentados por expertos en Farmacia 
• Los contenidos gráficos, esquemáticos y eminentemente prácticos con los que están concebidos recogen una información científica y práctica sobre aquellas disciplinas indispensables para el ejercicio profesional 
• Los ejercicios prácticos donde realizar el proceso de autoevaluación para mejorar el aprendizaje 
• Su especial hincapié en metodologías innovadoras 
• Las lecciones teóricas, preguntas al experto, foros de discusión de temas controvertidos y trabajos de reflexión individual 
• La disponibilidad de acceso a los contenidos desde cualquier dispositivo fijo o portátil con conexión a internet con conexión a internet 

Mantendrás tu conocimiento actualizado sobre las últimas evidencias científicas en farmacología aplicada al paciente con Edema Cerebral, integrando criterios clínicos avanzados y técnicas especializadas”

Incluye en su cuadro docente a profesionales pertenecientes al ámbito de la Farmacia, que vierten en este programa la experiencia de su trabajo, además de reconocidos especialistas de sociedades de referencia y universidades de prestigio. 

Su contenido multimedia, elaborado con la última tecnología educativa, permitirá al profesional un aprendizaje situado y contextualizado, es decir, un entorno simulado que proporcionará un estudio inmersivo programado para entrenarse ante situaciones reales. 

El diseño de este programa se centra en el Aprendizaje Basado en Problemas, mediante el cual el alumno deberá tratar de resolver las distintas situaciones de práctica profesional que se le planteen a lo largo del curso académico. Para ello, el profesional contará con la ayuda de un novedoso sistema de vídeo interactivo realizado por reconocidos expertos.    

Aprovecharás la modalidad 100% online sin horarios fijos, organizando tu estudio a tu ritmo y actualizando competencias clínicas de forma flexible y efectiva”

Actualizarás tus habilidades con las terapias emergentes para la Migraña, integrando estrategias clínicas avanzadas y protocolos basados en evidencia reciente. 

The effectiveness of the Relearning Method, has led TECH to use it in all its qualifications. With this system, the pharmacists will achieve a complete update, without the need to invest long hours of study and memorization. In this way, the reiteration of the key concepts will lead you to increase your knowledge of Advanced Neuropharmacology throughout the 3 modules that make up this Postgraduate diploma.

This academic course will allow you to be updated on the pathophysiological mechanisms of stroke patients, as well as the pharmacology related to its management”

Module 1. Pharmacology of Epilepsy, Migraine and Myasthenia Gravis

1.1. Adult Patient Seizures

1.1.1. Classification of Seizures
1.1.2. Differential diagnosis and clinical evaluation
1.1.3. Neuroimaging Studies in Diagnosis
1.1.4. Pharmacological treatment of seizures in the adult patient

1.2. Seizures in the pediatric patient

1.2.1. Classification of seizures in the pediatric patient
1.2.2. Differential diagnosis and clinical evaluation of seizures in the pediatric patient
1.2.3. Neuroimaging studies in the diagnosis of seizures in the pediatric patient
1.2.4. Febrile seizures in childhood

1.3. Status Epilepticus (SE) in the adult patient

1.3.1. Diagnosis and clinical evaluation of Status Epilepticus
1.3.2. Neurophysiological evaluation and neuroimaging in Status Epilepticus
1.3.3. Causes and triggers of Status Epilepticus in adults
1.3.4. Emergency management and treatment of Status Epilepticus in the adult patient

1.4. SE in the pediatric patient

1.4.1. Diagnosis and clinical evaluation of Status Epilepticus in the pediatric patient
1.4.2. Neurophysiological assessment and neuroimaging in pediatric Status Epilepticus
1.4.3. Causes and triggers of Status Epilepticus in children
1.4.4. Emergency management and treatment of Status Epilepticus in the pediatric patient

1.5. Management of Myasthenia Gravis (MG)

1.5.1. Classification of Myasthenia Gravis
1.5.2. Pharmacological Treatment of Myasthenia Gravis
1.5.3. Management of myasthenic crisis and acute exacerbations of myasthenia gravis
1.5.4. Immunomodulatory and biological therapies in myasthenia gravis

1.6. Headache and Migraine in the adult patient

1.6.1. Classification of primary and secondary headaches
1.6.2. Clinical evaluation and differential diagnosis of headache and Migraine in the adult patient
1.6.3. Initial therapeutic approach and management of episodic migraine
1.6.4. Migraine prophylaxis and prevention of chronic migraine headaches

1.7. Headache and Migraine in the pediatric patient

1.7.1. Classification of primary and secondary headaches in children
1.7.2. Clinical evaluation and differential diagnosis of headache and Migraine in the pediatric patient
1.7.3. Differences in the presentation and manifestation of Migraine in children and adults
1.7.4. Acute pharmacological treatment of migraine attacks in children

1.8. Hypertensive Emergencies

1.8.1. Classification and categories of hypertensive emergency
1.8.2. Clinical Evaluation and Diagnosis of Hypertensive Emergencies
1.8.3. Complementary tests and laboratory studies for the evaluation of hypertensive emergency
1.8.4. Differentiation between hypertensive emergency and hypertensive urgency

1.9. Pathophysiology of Epilepsy

1.9.1. Pharmacokinetics of antiepileptic drugs
1.9.2. Pharmacological interactions of antiepileptic drugs
1.9.3. Combination treatment strategies
1.9.4. Use of antiepileptic drugs in special populations

1.10. Emerging and developing therapies for Migraine treatment

1.10.1. Therapies specifically targeting the pathophysiology of Migraine
1.10.2. Monoclonal therapies directed against calcitonin gene-related peptide (CGRP) in Migraine
1.10.3. PDE4 inhibitors as an emerging treatment for Migraine
1.10.4. Use of monoclonal antibodies in the prophylactic treatment of Migraine

Module 2. Pharmacology of the Central Nervous System

2.1. Ischemic Strokes

2.1.1. Advances in the early diagnosis of ischemic stroke
2.1.2. Evaluation and classification of the risk of ischemic stroke in asymptomatic patients
2.1.3. Thrombolytic treatment strategies in the acute phase of ischemic stroke
2.1.4. Biomarkers in Ischemic Stroke

2.2. Management of hypertension in acute ischemic stroke

2.2.1. Current guidelines and protocols for the management of hypertension in acute ischemic stroke
2.2.2. Pharmacologic treatment of hypertension in the acute phase of ischemic stroke
2.2.3. Blood pressure control strategies in ischemic stroke with thrombolytic therapy
2.2.4. Endovascular therapy and blood pressure control in acute ischemic stroke

2.3. Oropharyngeal angioedema due to Alteplase

2.3.1. Risk factors for the development of oropharyngeal angioedema after Alteplase administration
2.3.2. Clinical and differential diagnosis of oropharyngeal angioedema in patients treated with Aateplase
2.3.3. Management and treatment of acute oropharyngeal angioedema by Alteplase
2.3.4. Evaluation and follow-up of patients with a history of oropharyngeal angioedema prior to administration of Alteplase

2.4. Hemorrhagic stroke: intracerebral hemorrhage (ICH)

2.4.1. Diagnosis and classification of intracerebral hemorrhage in hemorrhagic stroke
2.4.2. Medical and pharmacological treatment of acute intracerebral hemorrhage
2.4.3. Neurosurgical and endovascular management of intracerebral hemorrhage
2.4.4. Multidisciplinary approach in the care of the patient with intracerebral hemorrhage

2.5. Cerebral edema

2.5.1. Cytotoxic versus vasogenic cerebral edema
2.5.2. Clinical evaluation and imaging of cerebral edema
2.5.3. Pharmacological strategies for the reduction of cerebral edema in specific pathologies
2.5.4. Effect of cerebral edema

2.6. Opioid overdose

2.6.1. Pharmacokinetics and pharmacodynamics of opioids involved in overdose
2.6.2. Role of the hospital pharmacist in opioid overdose prevention and education
2.6.3. Management of opioid withdrawal in the hospital setting
2.6.4. Naloxone and its use as an antidote in opioid overdose reversal

2.7. Opioid Withdrawal Syndrome

2.7.1. Epidemiology and risk factors for the development of Opioid Withdrawal Syndrome
2.7.2. Clinical evaluation and diagnosis of Opioid Withdrawal Syndrome in hospitalized patients
2.7.3. Pharmacological management of Opioid Withdrawal Syndrome in the hospital setting
2.7.4. Use of opioid agonist and antagonist drugs in the treatment of withdrawal syndrome

2.8. Agitated Patient Management

2.8.1. Epidemiology and risk factors associated with agitation in hospitalized patients
2.8.2. Pharmacotherapy for the management of acute agitation in inpatients
2.8.3. Use of antipsychotics and benzodiazepines in the treatment of agitation
2.8.4. Safety and prevention of complications in the management of the agitated patient

2.9. Pharmacology of Mucolytics and Expectorants in Respiratory Diseases

2.9.1. Pharmacological interactions between analgesics and substances of abuse
2.9.2. Pharmacological strategies for acute pain management in patients with opioid abuse
2.9.3. Acute pain Treatment in patient with Alcohol abuse
2.9.4. Assessment and management of addiction risk in patients with substance abuse requiring analgesia

2.10. Alcohol Withdrawal Syndrome

2.10.1. Clinical evaluation and diagnosis of Alcohol Withdrawal Syndrome in hospitalized patients
2.10.2. Pharmacotherapy for the management of Alcohol Withdrawal Syndrome in the hospital setting
2.10.3. Use of benzodiazepines and other drugs in the treatment of Alcohol Withdrawal Syndrome
2.10.4. Role of the hospital pharmacist in the management of Alcohol Withdrawal Syndrome

Module 3. Pharmacology of the surgical and polytraumatized patient

3.1. Triage

3.1.1. Triage in emergency and disaster situations:
3.1.2. Triage systems used in the hospital setting and their characteristics
3.1.3. Role of the pharmacist in the triage process and emergency care
3.1.4. Pharmaceutical triage protocols in different clinical scenarios

3.2. Resuscitation in the polytraumatized patient (PPT)

3.2.1. Hospital pharmacy in the PPT resuscitation team
3.2.2. Pharmacology of resuscitation: drugs and therapies used in PPT
3.2.3. Fluid therapy in the polytraumatized patient: types of solutions and considerations
3.2.4. Analgesia and sedation in the polytraumatized patient

3.3. Cranioencephalic Trauma (CET)

3.3.1. Classification and Severity of CET
3.3.2. Pain management and sedation in patients with CET
3.3.3. Treatment of Intracranial Hypertension
3.3.4. Use of neuroprotective agents in CET

3.4. Reversal of anticoagulants

3.4.1. Importance of anticoagulant reversal in specific clinical situations
3.4.2. Risk-benefit assessment in anticoagulant reversal
3.4.3. Reversal of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH)
3.4.4. Antidotes and reversal agents for direct oral anticoagulants (OACDs)

3.5. Acute Pain Management

3.5.1. Classification and scales for the evaluation of acute pain
3.5.2. Principles and guidelines of pharmacological management of acute pain
3.5.3. Multimodal Analgesia
3.5.4. Intravenous, oral and transdermal analgesia

3.6. Spinal shock

3.6.1. Evaluation and classification of spinal shock
3.6.2. Medications to stabilize blood pressure in spinal cord shock
3.6.3. Pain Management in Patients with Spinal shock
3.6.4. Neuroprotective agents in spinal shock

3.7. Hypovolemic Shock

3.7.1. Evaluation and classification of Hypovolemic Shock shock
3.7.2. Fluid therapy and volume replacement in hypovolemic shock
3.7.3. Types of solutions and electrolytes used in volume replacement
3.7.4. Use of vasoactive agents in the management of hypovolemic shock

3.8. Penetrating Trauma

3.8.1. Evaluation and classification of patients with penetrating trauma
3.8.2. Initial management and pharmacological stabilization of the trauma patient
3.8.3. Use of hemostatic agents and pharmacologic hemostasis
3.8.4. Antibiotherapy in penetrating trauma patients

3.9. Open Fractures

3.9.1. Initial evaluation and emergency management of patients with open fractures
3.9.2. Use of analgesia and sedation in patients with open fractures
3.9.3. Adjuvant therapies in the acceleration of bone healing
3.9.4. Use of analgesics and anti-inflammatory drugs in the management of pain in open fractures

3.10. Moderate sedation

3.10.1. Indications and contraindications of moderate sedation
3.10.2. Evaluation and selection of the appropriate level of sedation for each patient
3.10.3. Management of anxiety and pain in procedures with moderate sedation
3.10.4. Monitoring and patient safety during moderate sedation

Get an effective update on pain management and sedation in CTE patients with the highest quality multimedia content”